Neurobiology of Aging
Volume 28, Issue 4 , Pages 568-578, April 2007

Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease

  • Alireza Kashani

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
  • ,
  • Catalina Betancur

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
  • ,
  • Bruno Giros

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
  • ,
  • Etienne Hirsch

      Affiliations

    • INSERM U679, CHU Pitié-Salpêtrière, 47 boulevard de l’Hôpital, 75013 Paris, France
  • ,
  • Salah El Mestikawy

      Affiliations

    • INSERM U513, Faculté de Médecine, Université Paris XII, 8 rue du Général Sarrail, 94010 Créteil Cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 49 81 36 06; fax: +33 1 49 81 36 85.

Received 5 October 2005; received in revised form 3 February 2006; accepted 14 February 2006. published online 27 March 2006.

Abstract 

Glutamatergic pathways play a key role in the functional organization of neuronal circuits involved in Parkinson disease (PD). Recently, three vesicular glutamate transporters (VGLUT1–3) were identified. VGLUT1 and VGLUT2 are responsible for the uploading of glutamate into synaptic vesicles and are the first specific markers of glutamatergic neurons available. Here, we analyzed the expression of VGLUT1 and VGLUT2 in autopsy tissues of PD patients and matched controls using Western blot and immunoautoradiography. VGLUT1 and VGLUT2 expression was increased in the Parkinsonian putamen by 24% and 29%, respectively (p<0.01). In contrast, only VGLUT1 was dramatically decreased in the prefrontal and temporal cortex of PD patients (∼50%, p<0.01 and p<0.001, respectively). These findings demonstrate the existence of profound alterations of glutamatergic transmission in PD, which are likely to contribute to the motor and cognitive impairments associated with the disease, and should thus be taken into account in the treatment of PD.

Keywords: Human, Parkinson disease, Vesicular glutamate transporter, VGLUT1, VGLUT2, Prefrontal cortex, Temporal cortex, Putamen, Western blot, Immunoautoradiography

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0197-4580(06)00076-5

doi:10.1016/j.neurobiolaging.2006.02.010

Neurobiology of Aging
Volume 28, Issue 4 , Pages 568-578, April 2007